Skip to main content
Equibles
PHAT logo

PHAT · Phathom Pharmaceuticals, Inc. · Analyst Estimates

Track PHAT — free

Use PHAT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PHAT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.20 +0.21 (+3.51%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$484.60M
Shares
80.90M
Volume · Oct 28 828.83K Avg daily vol (3M) 1.49M

Analyst Estimates

Compare analyst forecasts for Phathom Pharmaceuticals, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-22 20:06 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.16
-0.044
0.04
5
-0.03
-0.03
-0.03
-0.036
0
1
0
0
Revenue
USD
Publication date not stated
310.00M
315.24M
323.13M
10
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
0.54
0.96
1.51
5
1.08
1.08
1.11
1.43
0
0
1
0
Revenue
USD
Publication date not stated
435.00M
489.37M
543.30M
10
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.02
0.029
0.07
5
0.037
0.037
0.036
0.05
0
2
0
0
Revenue
USD
Publication date not stated
81.65M
84.82M
88.06M
10
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
0.04
0.11
0.16
5
0.11
0.11
0.11
0.19
1
3
0
0
Revenue
USD
Publication date not stated
95.20M
98.21M
102.49M
9
 — — — — — — — —
Key facts CIK 1783183 CUSIP 71722W107 13F (30d) 19 filings 19 filers Visit website Investor relations